Antitumor activity of interleukin-18 on mouse glioma cells

Journal of Immunotherapy

Volumn 23, Issue 2, 2000, Pages 184-189

  Kikuchi, Tetsuro ^a   Akasaki, Yasuharu ^a   Joki, Tatsuhiro ^a   Toshiaki, Abe ^a   Kurimoto, Masashi ^b   Ohno, Tsuneya ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Glioma; Immunotherapy; Interleukin 18; Tumor

Indexed keywords

GAMMA INTERFERON; GANGLIOTETRAOSYLCERAMIDE; IMMUNOGLOBULIN G; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOMA CELL; INOCULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; GLIOMA; GROWTH INHIBITORS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-18; KILLER CELLS, NATURAL; MICE; MICE, INBRED A; RECOMBINANT PROTEINS; STEREOTAXIC TECHNIQUES; TUMOR CELLS, CULTURED;

EID: 0034064238     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200003000-00002     Document Type: Article

References (18)

1. Brandes A, Soesan M, Fiorentino M. Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res 1991;11:1988-92.
2. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
3. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
4. Okada H, Giezeman-Smits KM, Tahara H, et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Therapy 1999; 6:219-26.
5. + T cell-dependent tumor rejection. J Exp Med 1991;174: 1291-8.
6. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995;2:96-106.
7. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
8. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378: 88-91.
9. Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156:4274-9.
10. Osaki T, Peron J M, Cai Q, et al. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 1998;160:1742-9.
11. Micallef MJ, Yoshida K, Kawai S, et al. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 1997;43:361-7.
12. Micallef MJ, Tanimoto T, Kohno K, et al. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 1997;57:4557-63.
13. Yoshida Y, Tasaki K, Kimurai M, et al. Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Th1 helper T cells. Anticancer Res 1998;18:333-5.
14. Sakamoto K, Hoshino H, Kiuchi Y, et al. Potential usefulness of a cultured glioma cell line induced by rous sarcoma virus in B10.A mouse as an immunotharapy model. Japan J Exp Med 1989;59: 173-80.
15. Kikuchi T, Joki T, Saitoh S, et al. Antitumor activity of interleukin 2 producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 1998;80:425-30.
16. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706.
17. Hyodo Y, Matsui K, Hayashi N, et al. IL-18 up-regulates perform mediated NK activity without increasing perform messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999;162:1662-8.
18. Coughlin CM, Salhany KE, Wysocka M, et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101: 1441-52.